Last updated: September 1, 2026
Asenapine maleate is a mature atypical antipsychotic with declining branded economics and fragmented generic competition. The market has two principal delivery formats: sublingual tablets marketed originally as Saphris and a transdermal patch marketed as Secuado. Generic erosion has reduced the commercial value of sublingual asenapine, while Secuado retains differentiation through its delivery system but operates in a crowded schizophrenia market.
The most important financial facts are:
- Saphris received U.S. approval in 2009 and lost practical branded exclusivity after generic entry.
- Generic asenapine sublingual tablets are approved in 5 mg and 10 mg strengths.
- Secuado was approved in 2019 and is protected primarily through formulation, device, and transdermal-delivery intellectual property rather than the basic active ingredient.
- AbbVie and its predecessors have not reported Saphris revenue as a separately material product in recent public filings.
- Secuado revenue is not generally disclosed as a standalone line item by its commercial stakeholders.
- Biosimilar risk is irrelevant because asenapine maleate is a small-molecule drug. Generic substitution and formulation competition are the main risks.
What is asenapine maleate and how is it used?
Asenapine maleate is an atypical antipsychotic approved for schizophrenia in adults and for acute manic or mixed episodes associated with bipolar I disorder in adults and pediatric patients within specified age ranges. The sublingual formulation is administered under the tongue and is available in 5 mg and 10 mg strengths. Secuado delivers asenapine through the skin using a once-daily transdermal system for adults with schizophrenia.[1,2]
Asenapine acts primarily through serotonin and dopamine receptor antagonism. Its sublingual administration avoids conventional gastrointestinal absorption and first-pass metabolism. The patch was developed to address adherence, swallowing, and administration issues rather than to create a new pharmacologic mechanism.
Product and company history
| Product |
Active ingredient |
Dosage form |
Original sponsor or commercial owner |
U.S. approval |
| Saphris |
Asenapine maleate |
Sublingual tablet |
Merck; later Forest, Allergan and AbbVie |
2009 |
| Secuado |
Asenapine |
Transdermal system |
Noven Pharmaceuticals |
2019 |
| Generic asenapine |
Asenapine maleate |
Sublingual tablet |
Multiple generic manufacturers |
From 2020 |
Merck developed Saphris and transferred the product through later corporate transactions involving Forest Laboratories, Actavis, Allergan and AbbVie. Noven, a specialist in transdermal drug delivery, developed Secuado. Hisamitsu Pharmaceutical acquired Noven in 2016, giving Hisamitsu a platform in the U.S. transdermal market.[3]
How large is the asenapine maleate market?
Public data do not support a reliable, current standalone global market-size estimate for asenapine maleate. Prescription-volume and sales databases may report the molecule by country, formulation, channel or manufacturer, but manufacturers generally do not disclose consolidated asenapine revenue in public filings.
The commercial market is best understood as two separate segments:
- A low-price, generic sublingual segment.
- A branded, differentiated transdermal segment centered on Secuado.
The sublingual segment has the larger installed prescribing base because it entered the market first and has generic alternatives. Its unit prices and brand profitability are constrained by generic substitution, payer formulary pressure and therapeutic competition.
Secuado has a higher potential net price per prescription because it is a branded delivery system. Its addressable market is narrower because it is approved for schizophrenia, not the full bipolar indication set associated with Saphris. The product also faces payer step edits and competition from long-acting injectable antipsychotics, oral generics and other branded oral agents.
Revenue exposure
| Revenue exposure |
Assessment |
| Saphris branded tablets |
Low and declining; revenue is not separately material in recent AbbVie reporting |
| Generic sublingual asenapine |
Volume may persist, but pricing is compressed |
| Secuado |
Higher strategic value per prescription, but limited disclosure and a narrower indication |
| Active pharmaceutical ingredient |
Commodity-like exposure relative to finished-dose products |
| Transdermal technology |
The strongest remaining differentiation in the franchise |
Saphris sales were commercially meaningful during the early post-launch period but did not become a major growth driver for Merck or AbbVie. The product competed against established atypical antipsychotics, including generic risperidone, olanzapine and quetiapine, as well as branded products such as aripiprazole and lurasidone.
When did asenapine lose exclusivity?
Asenapine’s core molecule and original sublingual product patents no longer provide meaningful U.S. market exclusivity. The commercial loss of exclusivity occurred when generic manufacturers entered the sublingual market, rather than on the nominal expiration date of a single patent.
The FDA approved the first generic versions of Saphris sublingual tablets in 2020. Generic products were approved in 5 mg and 10 mg strengths through the abbreviated new drug application pathway.[4]
Exclusivity timeline
| Event |
Approximate date |
Commercial effect |
| FDA approval of Saphris |
2009 |
Launch of branded sublingual asenapine |
| Supplemental pediatric approval |
2011 |
Expanded eligible patient population |
| FDA approval of Secuado |
2019 |
Introduced transdermal delivery |
| First generic sublingual approvals |
2020 |
Began erosion of Saphris pricing and share |
| Current market |
2024-2025 |
Generic sublingual competition; branded patch differentiation |
A precise patent-by-patent expiration analysis requires reviewing the current Orange Book records, patent-term adjustments and pediatric extensions for each listed patent. The underlying composition and sublingual-product protection is expired or commercially ineffective against approved generics. Secuado’s remaining protection is more relevant because it relates to the patch, delivery profile, manufacturing process and product configuration.
What patents protect asenapine maleate and Secuado?
The original Saphris estate included patents covering asenapine and pharmaceutical compositions. Those rights were directed primarily to the active compound, salts, formulations and administration methods. They do not prevent generic manufacturers from selling approved sublingual asenapine after the relevant patents and regulatory exclusivities ceased to block entry.
Secuado relies on a different patent strategy. Its protection is expected to center on:
- Transdermal delivery of asenapine.
- Adhesive and matrix composition.
- Drug-loading and release characteristics.
- Patch structure and manufacturing.
- Methods for treating schizophrenia with the transdermal system.
- Product-specific pharmacokinetic performance.
This creates a more durable barrier than the original molecule patent, but it does not eliminate the possibility of alternative delivery systems or an ANDA applicant challenging listed patents.
What is the Orange Book status of asenapine?
Saphris and Secuado have different Orange Book positions because they are different dosage forms and regulatory products. Saphris is listed as a sublingual tablet. Secuado is listed as a transdermal system. Orange Book patents and exclusivity codes should be assessed separately for each reference listed drug.[5]
The key legal distinction is that a generic sublingual product does not automatically substitute for a transdermal patch. A Secuado competitor would need to address the patch’s dosage form, delivery technology and listed patent estate. A generic tablet therefore erodes Saphris but does not directly eliminate Secuado’s product-level protection.
Are there Paragraph IV challenges to asenapine?
Paragraph IV litigation risk is concentrated in the Secuado product because the sublingual product already has generic competition. A Paragraph IV certification may assert that a listed patent is invalid, unenforceable or not infringed. The filing of an ANDA with a Paragraph IV certification can trigger patent litigation and, under the Hatch-Waxman framework, may create a 30-month stay of FDA approval in certain circumstances.[6]
For Saphris, Paragraph IV challenges were commercially relevant before generic approval. Their economic importance has fallen after generic entry.
For Secuado, a challenger would likely target:
- Whether the patch claims cover the proposed generic system.
- Whether the claims are obvious in view of prior transdermal systems.
- Whether the proposed product has the same active ingredient delivery characteristics.
- Whether method-of-use claims are infringed.
- Whether manufacturing or adhesive claims can be designed around.
A complete current litigation docket is not established by the product labels alone. Public litigation databases and district-court filings must be reviewed for any newly filed Secuado ANDA litigation or settlement.
What generic entry risks exist for asenapine?
Sublingual tablets
Generic entry risk is already realized. The original branded tablet faces:
- Lower average selling prices.
- Pharmacy-level substitution.
- Formulary exclusion.
- Reduced physician loyalty to Saphris.
- Limited ability to defend share through new indications.
Generic asenapine is clinically differentiated from some antipsychotics by its sublingual administration, but that differentiation is not sufficient to preserve branded pricing once FDA-approved tablets are available.
Transdermal patch
Secuado faces a slower and more technically complex generic pathway. The main risks are:
- An ANDA directed to an equivalent transdermal system.
- A 505(b)(2) product with a modified delivery design.
- Patent invalidity findings.
- A settlement allowing launch before patent expiry.
- A competing non-generic patch or long-acting formulation.
- Manufacturing scale-up failures that delay commercial entry but do not remove the long-term risk.
A transdermal generic may require greater development work than a conventional tablet because adhesive performance, skin irritation, drug release and residual drug content must be characterized. These requirements increase development costs but do not create a permanent barrier.
How does asenapine compare with competing antipsychotics?
| Drug or class |
Main competitive advantage |
Competitive pressure on asenapine |
| Quetiapine |
Broad bipolar and schizophrenia use; generic pricing |
Strong |
| Olanzapine |
Established efficacy and low generic cost |
Strong |
| Risperidone |
Generic availability and multiple formulations |
Strong |
| Aripiprazole |
Oral and long-acting injectable options |
Strong |
| Lurasidone |
Bipolar depression positioning |
Moderate to strong |
| Lumateperone |
Newer branded differentiation |
Moderate |
| Long-acting injectables |
Adherence and reduced daily dosing |
Strong against oral products |
| Secuado |
Once-daily transdermal delivery |
Differentiated but narrower |
Asenapine’s clinical positioning is constrained by the breadth of competing treatments. Oral generic antipsychotics have lower acquisition costs. Long-acting injectables address adherence more directly for some patients. Newer branded drugs compete through tolerability, indication breadth, cognition claims or bipolar depression positioning.
Secuado’s commercial case depends on patients who need asenapine’s pharmacology but have difficulty with oral administration, swallowing, daily tablet use or adherence. The patch’s value is therefore concentrated in a narrower patient segment.
What is the FDA regulatory status of asenapine?
Saphris is an FDA-approved sublingual tablet for schizophrenia and bipolar I disorder indications. Secuado is FDA-approved for the treatment of schizophrenia in adults. The FDA labeling identifies important safety risks associated with antipsychotic therapy, including increased mortality in elderly patients with dementia-related psychosis, metabolic effects, tardive dyskinesia, neuroleptic malignant syndrome and orthostatic hypotension.[1,2]
The regulatory framework creates limited near-term expansion potential:
- Saphris has already established its principal adult psychiatric indications.
- Secuado’s label is narrower than Saphris’s label.
- Pediatric expansion may support incremental volume but is unlikely to transform the franchise.
- New formulations would require additional clinical, chemistry, manufacturing and controls work.
- No biosimilar pathway applies.
What licensing deals affect asenapine?
The most important commercial transactions were corporate transfers rather than standalone licensing deals:
- Merck originally commercialized Saphris.
- Forest Laboratories obtained rights to Saphris in a transaction with Merck.
- Actavis acquired Forest, and Allergan later acquired Actavis.
- AbbVie acquired Allergan in 2020.
- Hisamitsu acquired Noven, the developer associated with Secuado.
These transactions moved asenapine between larger pharmaceutical portfolios but did not create a major disclosed royalty stream comparable with blockbuster licensing arrangements. Public filings do not identify asenapine as a material standalone contributor to consolidated revenue.
How strong is the patent estate for asenapine?
The estate is weak for the original sublingual molecule and stronger, but narrower, for the transdermal system.
| Patent category |
Current strategic strength |
| Core asenapine composition |
Weak; legacy protection has expired |
| Sublingual tablet formulation |
Weak to moderate; generic competition is established |
| Bipolar and schizophrenia methods |
Limited commercial blocking value after generic entry |
| Transdermal formulation |
Moderate to strong, depending on remaining claims |
| Adhesive and delivery technology |
Potentially meaningful for patch competition |
| Manufacturing process |
Relevant if difficult to design around |
| Device configuration |
Product-specific but vulnerable to alternative designs |
Patent strength should be measured by remaining term, claim breadth, validity under obviousness scrutiny, freedom to design around and the likelihood that a challenger will litigate. Secuado’s estate can support a branded period, but it does not create molecule-level exclusivity.
What is the financial trajectory for asenapine maleate?
The financial trajectory is mature-to-declining for sublingual asenapine and potentially stable-to-modest-growth for the patch if Secuado expands within its target population.
The expected trajectory is:
- Saphris revenue declined after generic entry.
- Generic tablet volume replaced a substantial portion of branded volume at lower prices.
- Secuado created a separate branded revenue opportunity based on delivery technology.
- Patch economics remain exposed to payer restrictions and competing adherence solutions.
- A future transdermal generic or competing patch would create the next major erosion event.
Asenapine is unlikely to become a major growth asset without a new indication, a materially improved formulation, a successful combination product or broader adoption of Secuado. The active ingredient itself has limited pricing power. Commercial value resides in formulation, delivery and distribution execution.
What generic launch scenarios should investors and licensees model?
Scenario 1: Continued generic sublingual erosion
This is the base case. Saphris remains commercially marginal, while generic manufacturers compete on price and channel access. The value of the sublingual franchise is primarily cash flow from residual branded prescriptions, authorized distribution and manufacturing relationships.
Scenario 2: Secuado remains differentiated
Secuado retains a specialized position among adults with schizophrenia who benefit from transdermal delivery. Revenue grows slowly or remains stable, but payer restrictions limit penetration.
Scenario 3: Secuado Paragraph IV challenge
An ANDA filing could produce litigation, a settlement or an at-risk launch. The commercial impact would depend on patent strength, launch timing and whether the generic reproduces the same patch characteristics.
Scenario 4: Alternative delivery competition
A competing long-acting injectable, transdermal product or novel oral formulation could reduce Secuado’s differentiation without directly challenging its patents. This is a market risk rather than a conventional patent risk.
What geographic markets matter?
The United States is the most important market for patent and generic-entry analysis because of the Hatch-Waxman system, Orange Book listings and ANDA substitution. European and other markets may have different patent terms, generic approval routes, reimbursement rules and product availability.
Asenapine’s global opportunity is limited by:
- Lower use of atypical antipsychotics in some markets.
- Local generic competition.
- National reimbursement controls.
- Different acceptance of sublingual and transdermal delivery.
- Limited evidence that the patch commands a premium outside the U.S.
U.S. launch timing remains the central valuation variable for any competing Secuado product.
Key Takeaways
- Asenapine maleate is a mature antipsychotic with limited molecule-level exclusivity.
- Saphris sublingual tablets face established generic competition and substantial price erosion.
- Secuado is the commercially differentiated asset because its protection is tied to transdermal delivery.
- Generic tablets do not directly substitute for the Secuado patch.
- Paragraph IV risk is more relevant to Secuado than to Saphris.
- Biosimilar competition does not apply.
- Public companies do not generally disclose standalone asenapine revenue, limiting precise market-size and product-level revenue analysis.
- Long-term value depends on Secuado’s payer access, adherence benefits, patent durability and resistance to alternative delivery systems.
FAQs
Is asenapine maleate still sold under the Saphris brand?
Yes. Saphris is the original branded sublingual asenapine product, but generic asenapine tablets have materially reduced its commercial importance.
Does Secuado have the same indications as Saphris?
No. Secuado is approved for schizophrenia in adults. Saphris has schizophrenia and bipolar I disorder indications, subject to FDA labeling and age-specific restrictions.
Can a generic asenapine tablet replace Secuado?
No. A sublingual tablet and a transdermal patch are different dosage forms and are not automatically substitutable at the pharmacy level.
Is asenapine maleate subject to biosimilar competition?
No. Asenapine is a small-molecule drug regulated through conventional generic pathways, not the biosimilar pathway used for biologics.
What would most increase the value of the asenapine franchise?
The strongest value drivers would be expanded use of Secuado, improved payer coverage, evidence supporting adherence or persistence, a new approved indication, or a delivery technology that is difficult for generic manufacturers to reproduce.
References
- U.S. Food and Drug Administration. (2023). Saphris (asenapine) sublingual tablets prescribing information.
- U.S. Food and Drug Administration. (2023). Secuado (asenapine) transdermal system prescribing information.
- Hisamitsu Pharmaceutical Co., Inc. (2016). Acquisition of Noven Pharmaceuticals, Inc.
- U.S. Food and Drug Administration. (2020). FDA approves first generic versions of Saphris for treatment of schizophrenia and bipolar disorder.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
